期刊
TRENDS IN BIOCHEMICAL SCIENCES
卷 39, 期 2, 页码 91-100出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibs.2013.12.004
关键词
-
资金
- National Institutes of Health (NIH)
- Pancreatic Cancer Action Network-American Association for Cancer Research (AACR)
- Lustgarten Pancreatic Cancer Foundation
- NIH
- American Cancer Society (ACS)
- Department of Defense (DOD)
- American Society of Radiation Oncology (ASTRO) Junior Faculty Career Research Training Award
- [T32 CA71341]
Oncogenic KRAS mutation is the signature genetic event in the progression and growth of pancreatic ductal adenocarcinoma (PDAC), an almost universally fatal disease. Although it has been appreciated for some time that nearly 95% of PDAC harbor mutationally activated KRAS, to date no effective treatments that target this mutant protein have reached the clinic. A number of studies have shown that oncogenic KRAS plays a central role in controlling tumor metabolism by orchestrating multiple metabolic changes including stimulation of glucose uptake, differential channeling of glucose intermediates, reprogrammed glutamine metabolism, increased autophagy, and macropinocytosis. We review these recent findings and address how they may be applied to develop new PDAC treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据